Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yang Yin Sheng Xue He Ji is a Traditional Chinese Medicine (TCM) oral liquid formulation primarily indicated for the treatment of blood and Yin deficiency, particularly manifesting as leukopenia or anemia in patients undergoing chemotherapy or radiotherapy. Developed and manufactured primarily by Zhejiang Jolly Pharmaceutical, the mixture contains a synergistic blend of botanical extracts including *Rehmannia glutinosa*, *Angelica sinensis*, and *Polygonum multiflorum*. Its primary mechanism of action involves the stimulation of hematopoietic function within the bone marrow and the modulation of the immune system to promote the recovery of white blood cell and hemoglobin levels. It is frequently used in integrative oncology settings in China to mitigate the hematologic toxicities associated with cytotoxic cancer treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yang Yin Sheng Xue He Ji.